Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Toxicity of reduced dose versus standard dose pegaspargase in adolescents and young adults with acute lymphoblastic leukemia

Blood (2025) 146 (Supplement 1): 3344.

https://doi.org/10.1182/blood-2025-3344

Published: 2025

Journal Articles

RAS mutations negate the favorable impact of NPM1 in older patients with newly diagnosed Acute Myeloid Leukemia treated with ven/HMA

Blood (2025) 146 (Supplement 1): 995.

https://doi.org/10.1182/blood-2025-995

Published: 2025

Journal Articles

Impact of antibiotic timing on survival outcomes in CD19 and BCMA CAR-T cell therapy

Serena Tharakan, Patrick Crorkin, Sana Ahmad, Jana Mihalyova, Shivani Handa, Jacques Azzi, Adriana Rossi, Shambavi Richard, Sundar Jagannath, Keren Osman, Alla Keyzner, Uroosa Ibrahim

Blood (2025) 146 (Supplement 1): 4113.

https://doi.org/10.1182/blood-2025-4113

Published: 2025

Journal Articles

Ruxolitinib and interferon alfa induce superior rates of complete peripheral blood count remission compared to anagrelide in hydroxyurea-exposed essential thrombocythemia

Tripura Vithala, Seungyeon Lee, Haley Roberts, Shivani Handa, Jennifer Vaughn, Sarah Wall, Ping Zhang, Andrew Srisuwananukorn

Blood (2025) 146 (Supplement 1): 3824.

https://doi.org/10.1182/blood-2025-3824

Published: 2025

Journal Articles

Phase 1b/2 study of axatilimab in combination with azacitidine in advanced Phase MPN, MDS/ MPN overlap and high-risk CMML

Uma Borate, Shivani Handa, Ying Huang, Kaitlyn Dvorak-Kornaus, Nicole Grieselhuber, Alice Mims

Blood (2025) 146 (Supplement 1): 5607.

https://doi.org/10.1182/blood-2025-5607

Published: 2025

Journal Articles

Phase 1b safety run-in study followed by Phase 2 study of ficlatuzumab, azacitidine and venetoclax in untreated Acute Myeloid Leukemia patients aged ≥ 60 years old

Blood (2025) 146 (Supplement 1): 3432.

https://doi.org/10.1182/blood-2025-3432

Published: 2025

Journal Articles

Evaluation of cytarabine consolidation dosing in older adult patients with Acute Myeloid Leukemia

Pooja Kumar, Deedra Nicolet, Tracelyn Freeman, Lexus Frazier, Allyson Waller, Megan Fleming, Michael Walker, Gregory Behbehani, James Blachly, Uma Borate, Nicole Grieselhuber, Shivani Handa, Jayanshu Jain, Karilyn Larkin, Meixiao Long, Ann-Kathrin Eisfeld, Alice Mims

Blood (2025) 146 (Supplement 1): 3408.

https://doi.org/10.1182/blood-2025-3408

Published: 2025

Journal Articles

Phase II study of clinical efficacy of venetoclax in combination with azacitidine in patients with therapy related myelodysplastic syndrome (t-MDS)

Uma Borate, Shivani Handa, Kaitlyn Dvorak-Kornaus, Ronan Swords, Curtis Lachowiez, Qiuhong Zhao, Yazan Madanat

Blood (2025) 146 (Supplement 1): 238.

https://doi.org/10.1182/blood-2025-238

Published: 2025

Journal Articles

Management and outcomes of patients diagnosed with chronic myeloid leukemia in blast Phase: A multicenter analysis by the h jean khoury cure CML consortium

Blood (2025) 146 (Supplement 1): 904.

https://doi.org/10.1182/blood-2025-904

Published: 2025

Journal Articles

Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study

Blood (2025) 146 (Supplement 1): 453.

https://doi.org/10.1182/blood-2025-453

Published: 2025

Journal Articles

Thrombocytopenia in myelofibrosis is characterized by inflammatory megakaryocytes with reduced G6B expression

Lilian Varricchio, Gohar Mosoyan, Sebastian Elghaity-Beckley, Md. Babu Mia, Shivani Handa, Christian Salib, John Mascarenhas, Ronald Hoffman

Blood (2025) 146 (13): 1612–1624.

https://doi.org/10.1182/blood.2024027363

Published: 2025

Includes: Supplemental data

Journal Articles

High-Resolution Chromosomal Microarrays Reveals Exon-Level Deletion in Chromosome 12q14.3 in Patients with Myeloproliferative Neoplasms

Joseph Tripodi, Shivani Handa, Christoph Schaniel, Daiva Ahire, Ronald Hoffman, Vesna Najfeld

Blood (2024) 144 (Supplement 1): 4520.

https://doi.org/10.1182/blood-2024-206440

Published: 2024

Journal Articles

Role of HMGA2 Overexpression Caused By Specific Genetic HMGA2 Aberrations in Disease Progression in Calreticulin-Mutated Myelofibrosis Patients

Christoph Schaniel, Shivani Handa, Joseph Tripodi, MD Babu Mia, Christian Salib, Jeff Vierstra, Allison J Cote, Daiva Ahire, Douglas Tremblay, Bridget Kelly Marcellino, John A Stamatoyannopoulos, Vesna Najfeld, Ronald Hoffman

Blood (2024) 144 (Supplement 1): 4512.

https://doi.org/10.1182/blood-2024-205834

Published: 2024

Journal Articles

TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms

Blood (2024) 144 (Supplement 1): 243.

https://doi.org/10.1182/blood-2024-206688

Published: 2024

Journal Articles

Impact of Pre-Transplant Molecular and Cytogenetic Remission on Outcomes of Allogeneic Stem Cell Transplant in Patients with Myelodysplastic Syndrome

Shivani Handa, Namrata Sonia Chandhok, Sudhamsh Reddy Desai, Asem Berkalieva, Erin Moshier, Douglas Tremblay, Lewis R. Silverman, Trent Wang, Uroosa Ibrahim, Aditi Shastri, Jonathan Feld

Blood (2023) 142 (Supplement 1): 3239.

https://doi.org/10.1182/blood-2023-190346

Published: 2023

Journal Articles

Oral Decitabine/Cedazuridine Is a Tolerable and Effective Ambulatory Regimen for Patients with Advanced Myeloproliferative Neoplasms

Ganesh Sivakumar, Shivani Handa, Andrew Srisuwananukorn, Douglas Tremblay, John Mascarenhas, Marina Kremyanskaya, Yelena Ginzburg, Xiaoli Wang, Ronald Hoffman

Blood (2023) 142 (Supplement 1): 1828.

https://doi.org/10.1182/blood-2023-178822

Published: 2023

Journal Articles

Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy

Shivani Handa, Jeong-Ok Lee, Andriy Derkach, Richard M. Stone, Alan Saven, Jessica K. Altman, Michael R. Grever, Kanti R. Rai, Madhulika Shukla, Shreya Vemuri, Skye Montoya, Justin Taylor, Omar Abdel-Wahab, Martin S. Tallman, Jae H. Park

Blood (2022) 140 (25): 2663–2671.

https://doi.org/10.1182/blood.2022016183

Published: 2022

Journal Articles

Obstetrical and Peri-Operative Management of Patients with Factor XI Deficiency - a Retrospective Observational Study

Shivani Handa, Michelle Sterpi, David Frankel, Katherine A. Hawkins, Etta B. Frankel

Blood (2021) 138 (Supplement 1): 495.

https://doi.org/10.1182/blood-2021-149322

Published: 2021

Journal Articles

Myelodysplastic Syndromes: Trends in Mortality, Costs of Hospitalizations, Length of Stay and Rate of Complications

Shivani Handa, MBBS, Giulia Petrone, MD MBBS, Kamesh Gupta, MBBS, Ahmad Khan, MD, Jasdeep Singh Sidhu, MBBS, Sridevi Rajeeve, MD

Blood (2019) 134 (Supplement_1): 1725.

https://doi.org/10.1182/blood-2019-129365

Published: 2019

Journal Articles

Etiologies and Predictors of 30-Day Readmission in Patients Undergoing Induction Chemotherapy for Acute Myeloid Leukemia

Shivani Handa, MBBS, Kamesh Gupta, MBBS, Jasdeep Singh Sidhu, MBBS, Giulia Petrone, MD MBBS, Sridevi Rajeeve, MD, Karan Jatwani, MBBS

Blood (2019) 134 (Supplement_1): 4759.

https://doi.org/10.1182/blood-2019-132180

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Toxicity of reduced dose versus standard dose pegaspargase in adolescents and young adults with acute lymphoblastic leukemia

RAS mutations negate the favorable impact of NPM1 in older patients with newly diagnosed Acute Myeloid Leukemia treated with ven/HMA

Impact of antibiotic timing on survival outcomes in CD19 and BCMA CAR-T cell therapy

Ruxolitinib and interferon alfa induce superior rates of complete peripheral blood count remission compared to anagrelide in hydroxyurea-exposed essential thrombocythemia

Phase 1b/2 study of axatilimab in combination with azacitidine in advanced Phase MPN, MDS/ MPN overlap and high-risk CMML

Phase 1b safety run-in study followed by Phase 2 study of ficlatuzumab, azacitidine and venetoclax in untreated Acute Myeloid Leukemia patients aged ≥ 60 years old

Evaluation of cytarabine consolidation dosing in older adult patients with Acute Myeloid Leukemia

Phase II study of clinical efficacy of venetoclax in combination with azacitidine in patients with therapy related myelodysplastic syndrome (t-MDS)

Management and outcomes of patients diagnosed with chronic myeloid leukemia in blast Phase: A multicenter analysis by the h jean khoury cure CML consortium

Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study

Thrombocytopenia in myelofibrosis is characterized by inflammatory megakaryocytes with reduced G6B expression

High-Resolution Chromosomal Microarrays Reveals Exon-Level Deletion in Chromosome 12q14.3 in Patients with Myeloproliferative Neoplasms

Role of HMGA2 Overexpression Caused By Specific Genetic HMGA2 Aberrations in Disease Progression in Calreticulin-Mutated Myelofibrosis Patients

TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms

Impact of Pre-Transplant Molecular and Cytogenetic Remission on Outcomes of Allogeneic Stem Cell Transplant in Patients with Myelodysplastic Syndrome

Oral Decitabine/Cedazuridine Is a Tolerable and Effective Ambulatory Regimen for Patients with Advanced Myeloproliferative Neoplasms

Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy

Obstetrical and Peri-Operative Management of Patients with Factor XI Deficiency - a Retrospective Observational Study

Myelodysplastic Syndromes: Trends in Mortality, Costs of Hospitalizations, Length of Stay and Rate of Complications

Etiologies and Predictors of 30-Day Readmission in Patients Undergoing Induction Chemotherapy for Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only